Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III pediatric booster study of Vaxem Hib in China
2014-005135-13Phase 3
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Haemophilus b conjugate vaccine in Haemophilus influenzae type b disease (Hib), meningitis, epiglottitis and 2 more (2 arms), sponsored by Novartis. Primary endpoint: Seroprotection rate at ≥1.0 µg/mL anti-PRP.
02
Drugs
Haemophilus b conjugate vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)meningitisepiglottitispneumoniaarthritis
Beyond the preview
Go deeper on 2014-005135-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005135-13.